Amryt Pharma (LON: AMYT) signed Tuesday an exclusive agreement with the pharmaceutical services company Romastru Trading to cover the distribution in Romania and Bulgaria of Lojuxta, a capsule treatment.
This is the fourth distribution agreement the bio-pharmaceutical company has signed in the last three months.
The agreement will be used to treat patients with homozygous familial hypercholesterolemia (HoFH), an inherited disease causing high blood levels of cholesterol. HoFH can be treated with Lojuxta, a medicine that contains the active substance of lomitapide.
The deal will help the company expand their activities for Lojuxta in Central and Eastern Europe. At the moment about 30 patients between Romania and Bulgaria were registered to have HoFH.
“We are pleased to have signed this agreement with Romastru, a long-established pharmaceutical services company based in Bucharest,” said Joe Wiley, Amryt Pharma’s CEO.
He continued: “Romastru’s reach across Romania and Bulgaria means that we can now provide comprehensive access to Lojuxta for adult patients suffering from HoFH in these territories.”
Romastru Trading, based in Bucharest, is part of Pharaon Healthcare Europe. The group provides a wide range of services that include medical, marketing research and distribution.Â
Amryt Pharma focuses on developing treatments for people with rare and orphan diseases. They will be completing further agreements across Europe, Middle East and Africa throughout 2018.
Shares were down 1 percent, trading at 19.60p as of 12:30pm (GMT).